

# Hot Topics for Congress and the USPTO: 101 Patent Eligibility and PTAB Director Review


September 14, 2022

## **PTAB Director Review**

#### United States v. Arthrex

- The Supreme Court decided Arthrex on June 21, 2021, which addressed the Constitution's Appointments Clause as it relates to Administrative Patent Judges ("APJs").
- The Supreme Court considered whether APJs are "principal officers" who must be appointed by the President with the advice and consent of the Senate, or (as the USPTO argued) whether they are "inferior officers" who can be appointed by the Secretary of Commerce.
- The Court held that "unreviewable authority wielded by APJs... is incompatible with their appointment by the Secretary to an inferior office."
- The Court's remedy held that the Director "may review final PTAB decisions and, upon review, may issue decisions himself on behalf of the Board."

 Post-Arthrex, the USPTO has implemented an Interim process for Director Review.



- The Office's Interim process is intended to further the USPTO's goal of promoting innovation through consistent and transparent decision-making and the issuance of strong patents.
- This Interim process complements three other PTAB procedures already in place:
  - Panel rehearing;
  - Internal review; and
  - The Precedential Opinion Panel ("POP").


- Under the Interim process, Director Review can be initiated sua sponte or requested by a party to a PTAB proceeding.
  - If Director Review is initiated sua sponte, the parties to the PTAB proceeding will be given notice and possibly the opportunity for briefing.
- Director Review may address any issue, including issues of fact and/or law.
  - Thus, Director Review decisions are not necessarily precedential.
- Director Review is de novo.
- Final written decisions by the Director are appealable to the U.S. Court of Appeals for the Federal Circuit.

# Director Review – Requests by a Party


- A party to a PTAB proceeding may request Director Review of a *final written decision* in an *inter partes* review or a post-grant review by concurrently:
  - (1) **filing a request for rehearing** by the Director of a PTAB decision, <u>and</u>
  - (2) **submitting a notification of the request** by email to Director\_PTABDecision\_Review@uspto.gov, copying counsel for all parties.

- After a *final written decision*, a party may request *either* Director Review or panel rehearing, *but not both*.
  - If a party requests panel rehearing, and the request is granted, a party may subsequently request Director Review of that decision.
  - If a party requests both Director Review and panel rehearing (either together, or in the alternative), the USPTO will treat that as a request for Director Review.

# Procedure for Director Review




#### Procedure for Director Review



# Director Review – Role of the Advisory Committee

- Requests for Director Review are routed to and considered by the Advisory Committee.
- The Advisory Committee consists of:
  - 11 members
  - Representatives from various USPTO business units
  - Provides an advisory recommendation to the Director
    - No member may participate in consideration of a request for Director Review if that member has a conflict of interest

## Director Review – Status of Requests



#### Director Review – Statistics

- Director Review has been requested 217 times and granted 12 times (8 initiated sua sponte and 4 granted on party request).
- Director Vidal has initiated Director Review suα sponte to address the following kinds of issues:
  - Denial of institution of inter partes review, see AviaGames, Inc. v. Skillz Platform, Inc. & Boehringer Ingelheim Animal Health USA Inc. v. Kansas State University Research Foundation
  - PTAB decision to deny Petitioner's request for rehearing, see, e.g., NXP USA, Inc. v. Impinj, Inc.
  - PTAB decision to deny institution based on the Board's discretionary authority under 35 U.S.C. § 314(a), see, e.g., Code200, UAB v. Bright Data, Ltd.
  - Determination of whether Petitioner is barred from pursuing IPR based on interference estoppel, see, e.g., Zynga, Inc. v. IGT.
  - Decision granting institution of inter partes review, see OpenSky Industries, LLC v. VLSI Technology LLC & Patent Quality Assurance, LLC v. VLSITechnology LLC.
  - To clarify the Office's binding guidance on the treatment of statements of the applicant in a challenged patent under 35 U.S.C. § 311(b), see, e.g., MED-EL Elektromedizinische Geräte Ges.m.b.H. v. Advanced Bionics AG.

#### Director Review – Statistics

Director PTABDecision Review@uspto.gov
571-272-7822

Patent Trial and Appeal

Paper 13 Date: September 7, 2022



UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE OFFICE OF THE UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

> NXP USA, INC., Petitioner,

> > V.

IMPINJ, INC., Patent Owner.

IPR2021-01556 Patent 10,776,198 B1

Before KATHERINE K. VIDAL, Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office.

DECISION
Granting Sua Sponte Director Review and Affirming the Decision Denying
Rehearing


- 8 of the last 9 grants of Director Review were instituted sua sponte by Director Vidal.
  - Nested Bean, Inc. v. Big Being Pty Ltd (Director Review initiated upon Patent Owner request to review the Board's Final Written Decision finding dependent claims unpatentable where independent claim was not unpatentable).

# **USPTO** Request for Comments

- The USPTO is reviewing the POP process in light of the Interim process and has requested public comments and suggestions.
- The USPTO's Interim process may change based on suggestions and comments from the public.
- The public is encouraged to submit suggestions and/or comments to Director\_Review\_Suggestions@uspto.gov.



# **USPTO** Request for Comments



#### More Information

- For more information on the Interim Director Review process, visit the USPTO *Arthrex* webpage:
  - https://www.uspto.gov/about-us/events/learn-about-interim-director-review-process-following-us-v-arthrex-inc
- For additional questions regarding the impact of Arthrex more generally, or on a specific proceeding, email trials@uspto.gov
- For comments or suggestions regarding the Interim Director Review process, visit the Federal Register webpage:
  - https://www.federalregister.gov/documents/2022/07/20/2022-15475/request-for-comments-on-director-review-precedential-opinion-panel-review-and-internal-circulation
    - Reminder: Comments close October 19, 2022

# Thank You